These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2981292)

  • 1. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer.
    Figueredo AT; Hryniuk WM; Strautmanis I; Frank G; Rendell S
    J Clin Oncol; 1985 Jan; 3(1):54-64. PubMed ID: 2981292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer.
    Evans WK; Feld R; Murray N; Pater J; Shelley W; Willan A; Osoba D; Levitt M; Coy P; Hodson I
    Semin Oncol; 1986 Sep; 13(3 Suppl 3):10-6. PubMed ID: 3020692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.
    Feld R; Evans WK; Coy P; Hodson I; MacDonald AS; Osoba D; Payne D; Shelley W; Pater JL
    J Clin Oncol; 1987 Sep; 5(9):1401-9. PubMed ID: 3040923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
    J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
    J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer.
    Einhorn LH; Crawford J; Birch R; Omura G; Johnson DH; Greco FA
    J Clin Oncol; 1988 Mar; 6(3):451-6. PubMed ID: 2832549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trimethoprim/sulfamethoxazole versus placebo: a double-blind comparison of infection prophylaxis in patients with small cell carcinoma of the lung.
    de Jongh CA; Wade JC; Finley RS; Joshi JH; Aisner J; Wiernik PH; Schimpff SC
    J Clin Oncol; 1983 May; 1(5):302-7. PubMed ID: 6321684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
    J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination cyclophosphamide, Adriamycin, and vincristine rapidly alternating with combination cisplatin and VP-16 in treatment of small cell lung cancer.
    Natale RB; Shank B; Hilaris BS; Wittes RE
    Am J Med; 1985 Sep; 79(3):303-8. PubMed ID: 2994472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC
    J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide.
    Johnson DH; Wolff SN; Hainsworth JD; Porter LL; Grosh WW; Hande KR; Greco FA
    J Clin Oncol; 1985 Feb; 3(2):170-5. PubMed ID: 2981981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial therapy with cisplatin plus VP-16 in small-cell lung cancer.
    Einhorn LH
    Semin Oncol; 1986 Sep; 13(3 Suppl 3):5-9. PubMed ID: 3020701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
    Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
    J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
    Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
    J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VP-16-213 in combination chemotherapy with chest irradiation for small-cell lung cancer: a randomized trial of the Piedmont Oncology Association.
    Jackson DV; Zekan PJ; Caldwell RD; Slatkoff ML; Harding RW; Case LD; Hopkins JO; Muss HB; Richards F; White DR
    J Clin Oncol; 1984 Dec; 2(12):1343-51. PubMed ID: 6096517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study.
    McCracken JD; Janaki LM; Crowley JJ; Taylor SA; Giri PG; Weiss GB; Gordon W; Baker LH; Mansouri A; Kuebler JP
    J Clin Oncol; 1990 May; 8(5):892-8. PubMed ID: 2159055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.